Dogs Need Better Aging Endpoints
Companion-animal translation looks strong only if it is tied to hard human aging deficits, not just biomarkers and hopeful owner anecdotes.
Route: dogs first, but measure like adults.
The edge is sensible: companion-animal models depend on human aging-deficit measurement. Pet dogs get real age-linked disease in real homes, with messy diets, owners, vets, infections, stairs, sofas, and all the other annoyances that lab mice are spared. That makes them useful before betting on humans.
What looks strong?
The logic. If an intervention claims to slow aging, it should move outcomes that matter across species: frailty, function, mobility, cognition, disease burden, survival. A dog walking better is not the same as a methylation clock moving. Both may matter. One is easier to fake with statistics.
What is thin?
The current edge is still a rationale, not proof. No anchor quote. No named trial. No endpoint hierarchy. No rule saying which canine signal maps to which human deficit. Without that, “translation” becomes a decorative word pasted on top of pet studies. We have seen this movie. The ending is usually a biomarker press release.
Next steps
Build the bridge explicitly: canine frailty index, gait, activity, vet-observed function, owner-reported quality of life, disease incidence, and mortality on one side; human grip strength, gait speed, VO2 max, multimodal clocks, and clinical events on the other. Predefine which changes count, which are noise, and which merely buy another grant cycle.
Then rank interventions by cross-species endpoint agreement, not by charisma.
This pathway was selected because it is the first idea-pathway dispatch and the edge has high confidence, but the stored material is still a seed rationale. That makes it a good case for explaining the route without overselling it: companion-animal models are promising only when tied to hard human aging-deficit measures.